Wastewater treatment device for synergistically catalyzing peracetic acid by Fe (II) and EGCG (Epigallocatechin Gallate)
Through the device that synergistically catalyzes peracetic acid by Fe(II) and EGCG, the reduction of Fe(III) is used to accelerate the organic degradation of peracetic acid, which solves the problem of low organic degradation efficiency in the prior art and realizes efficient wastewater treatment and cost reduction.
Patent Information
- Application Number
- CN202420855471.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Utility models(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-24
- Publication Date
- 2024-12-10
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing wastewater treatment devices are inefficient in degradation of organic matter, especially drug and endocrine interferon substances, which are difficult to effectively degrade.
The device that uses Fe(II) and EGCG to catalyze peracetic acid in a synergistic manner, and reduces Fe(III) to Fe(III) through a combination of a drug storage tank, oxidation reactor, ultrafiltration, ion exchanger and PH regulator using EGCG to reduce Fe(II) to Fe(III) to Fe(III) ), accelerate the degradation of organic matter by peracetic acid, improve wastewater treatment efficiency, and recover Fe(II) through an ion exchanger to reduce costs.
It significantly improves wastewater treatment efficiency, reduces operating costs, and simplifies equipment operation and ensures the safety of the treatment process.
Smart Images
Figure CN222138901U_ABST
Abstract
Description
Technical Field
[0001] The utility model belongs to the technical field of organic wastewater treatment devices, and specifically relates to a wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid. Background Art
[0002] With the advancement of detection technology, people have found that in addition to traditional pollutants, a large number of synthetic organic substances, especially drugs and endocrine disruptors, will enter the water environment with domestic wastewater, industrial wastewater or agricultural runoff. These organic substances are difficult to degrade through conventional process flow of sewage treatment plants. In recent years, many treatment technologies and methods have been proposed for this type of organic wastewater at home and abroad, among which advanced oxidation technology is considered to be the most promising, effective and environmentally friendly treatment method. Advanced oxidation technology refers to the technology of degrading organic pollutants by generating active substances such as hydroxyl radicals (HO·), sulfate radicals (SO4·) or singlet oxygen (1O2) in the reaction. Because free radicals have strong oxidizing properties, pollutants can be degraded into small molecular organic matter to improve the biodegradability of pollutants or directly mineralize them into CO2, H2O and inorganic salts.
[0003] At present, the main oxidants for advanced oxidation are persulfate, hydrogen peroxide, etc. Compared with these oxidants, peracetic acid (PAA) is an environmentally friendly disinfectant with low toxic side effects; it has strong oxidizing properties, and its reduction potential is 1.0-1.96V; it has a broad spectrum of bactericidal activity and is cheap. In order to improve the potential of PAA to produce active substances, transition metal activation, thermal activation, ultraviolet activation and other means are usually used. And homogeneous metal activation is the most efficient method. Compared with literature and laboratory tests, Fe(II) activation has the advantages of being green and environmentally friendly, low toxicity and low cost, and Fe(II) reacts with PAA faster. However, when Fe(II) is converted into Fe(III) in large quantities, Fe(III) will accumulate to form iron oxide sludge, which will reduce the degradation efficiency of organic matter by the Fe(II) / PAA system.
[0004] In summary, the organic matter degradation efficiency of the wastewater treatment device in the prior art is low. Utility Model Content
[0005] The utility model provides a wastewater treatment device for synergistically catalyzing peracetic acid with Fe(II) and EGCG, aiming to solve the problem of low organic matter degradation efficiency of wastewater treatment devices in the prior art.
[0006] In order to solve the above technical problems, the technical solution adopted by the utility model is:
[0007] A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid, comprising a drug storage tank, an oxidation reactor, an ultrafilter, an ion exchanger and a pH regulator, wherein the wastewater to be treated is sequentially treated by the oxidation reactor, the ultrafilter, the ion exchanger and the pH regulator and then output;
[0008] The drug storage tanks include a first drug storage tank for storing EGCG, a second drug storage tank for storing peracetic acid, and a third drug storage tank for storing Fe(II). The first drug storage tank, the second drug storage tank, and the third drug storage tank all supply agents to the oxidation reactor.
[0009] A further improved solution: the wastewater treatment device for the synergistic catalysis of peracetic acid by Fe(II) and EGCG also includes a flushing component for flushing the ion exchanger, and the liquid generated after the flushing component flushes the ion exchanger flows back to the third drug storage tank.
[0010] Based on the above technical solution: the wastewater treatment device for the synergistic catalysis of peracetic acid by Fe(II) and EGCG also includes a flushing component for flushing the ion exchanger, and the flushing component is used to backwash the ion exchanger, thereby recovering Fe(II) in the ion exchanger and reducing the cost of wastewater treatment.
[0011] A further improved solution: the ion exchanger is provided with a flushing pipe, the flushing assembly includes a flushing medicine box, the flushing medicine box is connected to the flushing pipe, and the ion exchanger is also provided with a reflux pipe, one end of the reflux pipe is connected to the ion exchanger, and the other end of the reflux pipe is connected to the third medicine storage tank.
[0012] Based on the above technical solution: the ion exchanger is provided with a flushing pipe, the flushing assembly includes a flushing medicine box, the flushing medicine box is communicated with the flushing pipe, and the ion exchanger is also provided with a reflux pipe. By setting the reflux pipe, the setting positions of the ion exchanger and the third medicine storage tank are not restricted, and the positions of the third medicine storage tank and the ion exchanger can be freely set.
[0013] A further improved solution: a concentrated water discharge pipe is provided on the ultrafilter.
[0014] Based on the above technical solution: the ultrafilter is provided with a concentrate discharge pipe, which is used to discharge the concentrate in the ultrafilter.
[0015] A further improved solution: the first drug storage tank, the second drug storage tank and the third drug storage tank all supply drugs to the oxidation reactor through independent drug inlet pipes.
[0016] Based on the above technical solution: the first drug storage tank, the second drug storage tank and the third drug storage tank all supply drugs to the oxidation reactor through independent drug inlet pipes, the setting position of the oxidation reactor is not restricted, and the wastewater treatment device is easy to maintain.
[0017] A further improved solution: each of the drug inlet pipes is provided with a metering pump for supplying an independent drug to the oxidation reactor.
[0018] Based on the above technical solution: each of the drug inlet pipes is provided with a metering pump for supplying independent reagents to the oxidation reactor. The metering pump can accurately measure the amount of reagents supplied to the oxidation reactor, which is beneficial to the chemical reaction of the oxidation reactor and improves the wastewater treatment accuracy of the oxidation reactor.
[0019] A further improved solution: the oxidation reactor is provided with a stirrer for stirring the liquid in the oxidation reactor.
[0020] Based on the above technical solution: the oxidation reactor is provided with an agitator for stirring the liquid in the oxidation reactor. The agitator stirs the liquid in the oxidation reactor, thereby improving the reaction efficiency of the liquid in the oxidation reactor and further improving the wastewater treatment efficiency.
[0021] A further improved solution: the stirrer includes a stirring component and a control component for controlling the working time of the stirring component.
[0022] Based on the above technical solution: the agitator includes a stirring component and a control component for controlling the working time of the stirring component, and the control component is used to control the stirring time of the stirring component, so that the liquid in the oxidation reactor can be evenly stirred, further improving the wastewater treatment efficiency.
[0023] A further improved solution is that the oxidation reactor supplies the liquid treated by the oxidation reactor to the ultrafilter via a water pump.
[0024] Based on the above technical solution: the oxidation reactor supplies the liquid treated by the oxidation reactor to the ultrafilter through a water pump. The water pump can effectively supply the liquid treated by the oxidation reactor to the ultrafilter, thereby improving the stability of the wastewater treatment device during operation.
[0025] A further improved solution: the water pump is a centrifugal pump.
[0026] Based on the above technical solution, the water pump is a centrifugal pump, which is highly efficient and easy to maintain.
[0027] The beneficial effects of the utility model are:
[0028] A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid, wherein the wastewater to be treated is sequentially treated by the oxidation reactor, ultrafilter, ion exchanger and pH regulator and then output; the drug storage tank comprises a first drug storage tank for storing EGCG, a second drug storage tank for storing peracetic acid and a third drug storage tank for storing Fe(II), and the first drug storage tank, the second drug storage tank and the third drug storage tank all supply drugs to the oxidation reactor. Fe(III) is reduced to Fe(II) by the highly reducing complex reducing agent EGCG, accelerating the cycle of Fe(III) / Fe(II), improving the efficiency of PAA in degrading organic matter, and thus improving the wastewater treatment efficiency. In addition, the wastewater treatment device has low operating costs, and the equipment is simple and safe to operate. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the technical solutions of the embodiments of the utility model, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the utility model and therefore should not be regarded as limiting the scope. For ordinary technical users in this field, other relevant drawings can be obtained based on these drawings without paying creative labor.
[0030] Figure 1 It is a schematic diagram of the first direction of a wastewater treatment device for the utility model that synergistically catalyzes peracetic acid using Fe(II) and EGCG.
[0031] Figure 2 It is a schematic diagram of the second direction of a wastewater treatment device of the utility model for synergistically catalyzing peracetic acid with Fe(II) and EGCG.
[0032] Figure 3 It is a schematic diagram of the third direction of a wastewater treatment device for synergistically catalyzing peracetic acid with Fe(II) and EGCG according to the utility model.
[0033] Description of the numbers in the figure:
[0034] 1-oxidation reactor; 11-agitator; 2-ultrafilter; 21-concentrated water discharge pipe; 3-ion exchanger; 4-PH regulator; 5-first drug storage tank; 6-second drug storage tank; 7-third drug storage tank; 71-reflux pipe; 8-flushing assembly; 81-flushing drug box; 9-drug inlet pipe; 10-water pump. DETAILED DESCRIPTION
[0035] The following will be combined with the drawings in the embodiments of the utility model to clearly and completely describe the technical solutions in the embodiments of the utility model. It should be understood that the specific embodiments described herein are only used to explain the utility model and are not used to limit the utility model. Based on the embodiments of the utility model, all other embodiments obtained by users of the technology in this field without creative work belong to the protection scope of the utility model.
[0036] refer to Figures 1 to 3 This embodiment provides a wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid, comprising a drug storage tank, an oxidation reactor 1, an ultrafilter 2, an ion exchanger 3 and a pH regulator 4, wherein the wastewater to be treated is sequentially treated by the oxidation reactor 1, the ultrafilter 2, the ion exchanger 3 and the pH regulator 4 and then output;
[0037] The drug storage tanks include a first drug storage tank 5 for storing EGCG, a second drug storage tank 6 for storing peracetic acid, and a third drug storage tank 7 for storing Fe(II). The first drug storage tank 5, the second drug storage tank, and the third drug storage tank 7 all supply drugs to the oxidation reactor 1.
[0038] EGCG: Epigallocatechin gallate.
[0039] Wherein: the wastewater treatment device for the synergistic catalysis of peracetic acid by Fe(II) and EGCG also includes a flushing component 8 for flushing the ion exchanger 3 , and the liquid generated after the flushing component 8 flushes the ion exchanger 3 flows back to the third drug storage tank 7 .
[0040] Specifically: the ion exchanger 3 is provided with a flushing pipe, the flushing assembly 8 includes a flushing medicine box 81, the flushing medicine box 81 is communicated with the flushing pipe, the ion exchanger 3 is also provided with a reflux pipe 71, one end of the reflux pipe 71 is communicated with the ion exchanger 3, and the other end of the reflux pipe 71 is communicated with the third medicine storage tank 7.
[0041] Wherein: the ultrafilter 2 is provided with a concentrated water discharge pipe 21 .
[0042] refer to Figures 1 to 3 Specifically: the first drug storage tank 5 , the second drug storage tank and the third drug storage tank 7 all supply drugs to the oxidation reactor 1 through independent drug inlet pipes 9 .
[0043] Each of the drug inlet pipes 9 is provided with a metering pump for supplying an independent agent to the oxidation reactor 1. The drug inlet pipes 9 are also connected in series with a control valve, and each of the drug inlet pipes 9 is connected in series with at least two control valves.
[0044] Wherein: the oxidation reactor 1 is provided with a stirrer 11 for stirring the liquid in the oxidation reactor 1 .
[0045] The stirrer 11 includes a stirring component and a control component for controlling the working time of the stirring component.
[0046] The oxidation reactor 1 supplies the liquid treated by the oxidation reactor 1 to the ultrafilter 2 via a water pump 10 .
[0047] The water pump 10 is a centrifugal pump.
[0048] Among them, a wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid also includes a wastewater tank and a water collecting tank. The wastewater to be treated is stored in the wastewater tank, and the treated wastewater output by the pH regulator 4 is stored in the water collecting tank. The liquid in the water collecting tank can be discharged directly.
[0049] The wastewater tank supplies wastewater to the oxidation reactor 1 through a supply pump. The wastewater tank can be connected to the oxidation reactor 1 through a water supply pipe. The supply pump is connected in series to the water supply pipe, and a control valve can also be provided on the water supply pipe.
[0050] The oxidation reactor 1 can be connected to the ultrafilter 2 through a first pipeline, and the water pump 10 can be connected in series to the first pipeline. A control valve can be connected in series to the first pipeline.
[0051] The ultrafilter 2 and the ultrafilter exchanger can be communicated through a second pipeline, and a control valve can be connected in series to the second pipeline.
[0052] refer to Figures 1 to 3 The ion exchanger 3 can be connected to the water collecting tank through the third pipeline, and the pH regulator 4 can be connected to the third pipeline through the third pipeline. A control valve can be set on the third pipeline. A pH sensor is also set on the third pipeline. The control unit of the pH regulator 4 controls the operation of the pH regulator 4 through the parameters detected by the pH sensor.
[0053] A control valve can be connected in series to the return pipe.
[0054] The working principle of this embodiment:
[0055] The drug storage tanks include a first drug storage tank 5 for storing EGCG, a second drug storage tank 6 for storing peracetic acid, and a third drug storage tank 7 for storing Fe(II). The first drug storage tank 5, the second drug storage tank, and the third drug storage tank 7 all supply drugs to the oxidation reactor 1. The wastewater treatment device uses Fe(II) and EGCG to synergistically catalyze peracetic acid to improve the degradation efficiency of the oxidation reactor 1 for organic pollutants, and at the same time recycles Fe(II) through ion exchange, reduces the dosage and reduces the discharge of iron-containing sludge. The wastewater treatment device has low operating costs and is simple and safe to operate.
[0056] The present utility model is not limited to the above optional implementation modes. Under the premise of not conflicting with each other, the various schemes can be combined arbitrarily. Anyone can derive other forms of products under the inspiration of the present utility model. However, no matter what changes are made in their shapes or structures, all technical schemes that fall within the scope defined by the claims of the present utility model fall within the protection scope of the present utility model.
Claims
1. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid, characterized in that: It includes a drug storage tank, an oxidation reactor, an ultrafilter, an ion exchanger and a pH regulator, and the wastewater to be treated is sequentially treated by the oxidation reactor, the ultrafilter, the ion exchanger and the pH regulator before being output; The drug storage tanks include a first drug storage tank for storing EGCG, a second drug storage tank for storing peracetic acid, and a third drug storage tank for storing Fe(II). The first drug storage tank, the second drug storage tank, and the third drug storage tank all supply agents to the oxidation reactor.
2. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 1, characterized in that: The wastewater treatment device for the synergistic catalysis of peracetic acid by Fe(II) and EGCG also includes a flushing component for flushing the ion exchanger, and the liquid generated after the flushing component flushes the ion exchanger flows back to the third drug storage tank.
3. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 2, characterized in that: The ion exchanger is provided with a flushing pipe, the flushing assembly includes a flushing medicine box, the flushing medicine box is connected to the flushing pipe, and the ion exchanger is also provided with a reflux pipe, one end of the reflux pipe is connected to the ion exchanger, and the other end of the reflux pipe is connected to the third medicine storage tank.
4. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 1, characterized in that: The ultrafilter is provided with a concentrated water discharge pipe.
5. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 1, characterized in that: The first drug storage tank, the second drug storage tank and the third drug storage tank all supply drugs to the oxidation reactor through independent drug inlet pipes.
6. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 5, characterized in that: Each of the drug inlet pipes is provided with a metering pump for supplying independent drugs to the oxidation reactor.
7. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 1, characterized in that: The oxidation reactor is provided with a stirrer for stirring the liquid in the oxidation reactor.
8. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 7, characterized in that: The stirrer comprises a stirring component and a control component for controlling the working time of the stirring component.
9. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 1, characterized in that: The oxidation reactor supplies the liquid treated in the oxidation reactor to the ultrafilter via a water pump.
10. A wastewater treatment device for Fe(II) and EGCG synergistically catalyzing peracetic acid according to claim 9, characterized in that: The water pump is a centrifugal pump.